trending Market Intelligence /marketintelligence/en/news-insights/trending/Lx3kJnTc-SGzyqfcM94RDw2 content esgSubNav
In This List

Health Canada approves Pediapharm ear infection drug

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Health Canada approves Pediapharm ear infection drug

Health Canada approved Pediapharm Inc.'s Otixal for the treatment of acute otitis media with tympanostomy tubes in pediatric patients.

Otixal is an antibiotic and steroid combination ear drop.